Orosomucoid 1 interacts with S100A12 and activates ERK signalling to expedite the advancement of bladder cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Liu Z;Liu Z; Pu X; Pu X
  • Source:
    Cell adhesion & migration [Cell Adh Migr] 2025 Dec; Vol. 19 (1), pp. 1-11. Date of Electronic Publication: 2024 Dec 07.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101469464 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1933-6926 (Electronic) Linking ISSN: 19336918 NLM ISO Abbreviation: Cell Adh Migr Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Austin, Tex. : Landes Bioscience
    • Subject Terms:
      Urinary Bladder Neoplasms*/metabolism ; Urinary Bladder Neoplasms*/pathology ; Urinary Bladder Neoplasms*/genetics ; MAP Kinase Signaling System* ; Cell Proliferation* ; Cell Movement* ; Apoptosis* ; S100A12 Protein*/metabolism ; S100A12 Protein*/genetics; Humans ; Cell Line, Tumor ; Orosomucoid/metabolism ; Gene Expression Regulation, Neoplastic ; Protein Binding
    • Abstract:
      The research endeavors to expound the role of ORM1 in bladder cancer (BCa) and the implied response mechanism. RT-qPCR and Western blotting examined ORM1 and S100A12 expression. Functional experiments assessed the cellular phenotypes. HDOCK and Co-IP confirmed the interaction of ORM1 and S100A12. Western blotting tested apoptosis- and ERK signaling-associated proteins. ORM1 and S100A12 were abundant in the BCa cells. ORM1 or S100A12 loss impaired cell proliferation, migration, and invasion, and aggravated cell apoptosis. ORM1 interacted with S100A12. ORM1 knockdown down-regulated S100A12 expression and inactivated ERK signaling.S100A12 overexpression or ERK activator reversed the impacts of ORM1 interference on ERK signaling and BCa cells. ORM1 mightdrive BCa via binding to S100A12 and activating ERK signaling.
    • References:
      Sci Rep. 2020 Feb 3;10(1):1724. (PMID: 32015423)
      Immunology. 2015 Jan;144(1):79-90. (PMID: 24975020)
      Cells. 2021 Sep 22;10(10):. (PMID: 34685488)
      Gastroenterol Res Pract. 2020 Feb 26;2020:2868373. (PMID: 32184815)
      Biophys Rev. 2018 Dec;10(6):1617-1629. (PMID: 30382555)
      Biomed Res Int. 2021 Jul 05;2021:4340950. (PMID: 34285910)
      BMC Genom Data. 2022 Aug 1;23(1):60. (PMID: 35909123)
      Sci Rep. 2023 Sep 21;13(1):15687. (PMID: 37735575)
      Life Sci. 2017 Dec 15;191:253-258. (PMID: 29080693)
      Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118677. (PMID: 32057918)
      J Physiol Biochem. 2015 Jun;71(2):329-40. (PMID: 25711902)
      Cancer Manag Res. 2019 Mar 27;11:2449-2456. (PMID: 31118765)
      Indian J Cancer. 2014 Mar;51 Suppl 3:e67-71. (PMID: 25818737)
      Onco Targets Ther. 2019 Jul 02;12:5163-5175. (PMID: 31456643)
      Cancer. 2016 Mar 15;122(6):842-51. (PMID: 26773572)
      Int J Mol Sci. 2023 Sep 26;24(19):. (PMID: 37833982)
      FEBS Open Bio. 2020 Oct;10(10):2107-2121. (PMID: 32865871)
      Bioengineered. 2021 Dec;12(1):8822-8832. (PMID: 34654351)
      Clin Chim Acta. 2018 Jan;476:54-59. (PMID: 29146477)
      Pathol Int. 2020 Jul;70(7):403-412. (PMID: 32202379)
      J Cancer Res Clin Oncol. 2024 Feb 19;150(2):96. (PMID: 38372785)
      Am J Cancer Res. 2016 Jan 15;6(2):331-40. (PMID: 27186407)
      Front Oncol. 2020 Jan 09;9:1484. (PMID: 31993369)
      BMC Cancer. 2020 Mar 30;20(1):261. (PMID: 32228516)
      BMC Cancer. 2023 Aug 5;23(1):725. (PMID: 37543645)
      Asian Pac J Cancer Prev. 2015;16(7):2725-9. (PMID: 25854354)
      Jpn J Clin Oncol. 2020 Mar 9;50(3):254-260. (PMID: 31829429)
      Sci Rep. 2023 Aug 28;13(1):14092. (PMID: 37640741)
      Cell Death Dis. 2021 May 25;12(6):537. (PMID: 34035231)
      Int J Mol Sci. 2019 May 21;20(10):. (PMID: 31117237)
      Front Mol Biosci. 2022 Feb 16;8:789658. (PMID: 35252345)
      CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
      Immunology. 2024 Mar;171(3):365-376. (PMID: 38013255)
      Gastroenterol Res Pract. 2016;2016:2632703. (PMID: 26880885)
      Bosn J Basic Med Sci. 2022 Oct 23;22(6):949-958. (PMID: 35765957)
      Tumour Biol. 2016 Apr;37(4):4621-31. (PMID: 26508026)
      Adv Sci (Weinh). 2023 Sep;10(25):e2300110. (PMID: 37414584)
      Front Immunol. 2020 Dec 17;11:590618. (PMID: 33391264)
      Acta Med Acad. 2021 Apr;50(1):143-156. (PMID: 34075770)
    • Contributed Indexing:
      Keywords: Extracellular signal-regulated kinase; S100 calcium binding protein A12; metastasis; orosomucoid 1; urinary bladder neoplasm
    • Accession Number:
      0 (S100A12 Protein)
      0 (Orosomucoid)
    • Publication Date:
      Date Created: 20241207 Date Completed: 20241207 Latest Revision: 20241213
    • Publication Date:
      20241213
    • Accession Number:
      PMC11633163
    • Accession Number:
      10.1080/19336918.2024.2434209
    • Accession Number:
      39644201